Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multi-Center, Open-Label, Phase 1/2 Clinical Trial to Evaluate the Safety and Anti-Tumor Activity of AB-101 Monotherapy and AB-101 With Immunotherapy in Patients With Relapsed/Refractory Non-Hodgkin Lymphoma of B-Cell Origin.

NCT04673617 is registered in ClinicalTrials.gov with Artiva Biotherapeutics, Inc. as lead sponsor.

NCT NCT04673617
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04673617 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multi-Center, Open-Label, Phase 1/2 Clinical Trial to Evaluate the Safety and Anti-Tumor Activity of AB-101 Monotherapy and AB-101 With Immunotherapy in Patients With Relapsed/Refractory Non-Hodgkin Lymphoma of B-Cell Origin.
Lead sponsor
Artiva Biotherapeutics, Inc.
Phase
Phase 1/2
Overall status
Completed
Start date
March 29, 2021
Completion date
October 6, 2025
Enrollment
45 (actual)
Sites
21

Conditions

As the registry lists them; a condition with its own page is linked.

non hodgkin lymphoma